Today: 17 May 2026
QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst
17 May 2026
2 mins read

QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst

New York, May 17, 2026, 17:02 EDT

  • QS ended Friday at $8.01, dropping 6.9% for the session. That’s still up around 6.6% from the previous Friday’s finish.
  • U.S. markets are closed for the weekend. Up next is watching if investors stick with QuantumScape’s Q2 production ramp story.
  • The company is still in the development stage and hasn’t generated any revenue from its main business yet.

QuantumScape stock starts the week after a choppy stretch: shares tumbled 6.86% to $8.01 on Friday, but for the week still ended in the green. Traders jumped in midweek on the company’s solid-state battery pitch, with more than 60 million shares moving Wednesday as QS hit $8.66 before falling back.

That’s in focus now since the stock market did not trade Sunday. Nasdaq’s usual hours are Monday to Friday, from 9:30 a.m. to 4:00 p.m. Eastern. For the next few sessions, the company’s shares will likely move more on last week’s rally and whether it holds after Friday’s profit-taking, rather than weekend news.

QuantumScape’s investor page continues to show its April 22 first-quarter results as its most recent news. So last week’s move in the stock didn’t follow a fresh company release. Instead, the market kept debating if the company is really shifting from lab-scale success to something it can reproduce in production.

Eagle Line, QuantumScape’s automated pilot production line, is at the center of things. The company said it finished installing Eagle Line in the first quarter. Start-up operations are underway and the line is already producing early QSE-5 cells. QuantumScape plans to boost QSE-5 output in the second quarter for car makers and other customers.

QuantumScape is working on solid-state lithium-metal batteries that use a solid ceramic separator instead of the liquid electrolyte found in most lithium-ion cells. Shares tend to move on any production news. In its 10-Q, the company said its main operations had not started yet and that as of March 31 it hadn’t brought in revenue from its main business.

QuantumScape CEO Siva Sivaram told investors the company saw “substantive progress” on cell quality and reliability after putting advanced AI models into Eagle Line. He also described the data-center opportunity as “obvious and compelling,” putting a new angle next to QuantumScape’s main electric-vehicle efforts. The Motley Fool

Chief Financial Officer Kevin Hettrich reported first-quarter customer billings at $11 million. Customer billings counts invoices sent to customers and partners. Hettrich said this metric is “not a substitute for revenue under U.S. GAAP,” referring to the U.S. accounting standards. The Motley Fool

QuantumScape posted a net loss of $100.8 million for the first quarter. The adjusted EBITDA loss came in at $63.2 million. Liquidity stood at $904.7 million. Adjusted EBITDA, which leaves out interest, taxes, depreciation, amortization and stock-based compensation, is a non-GAAP metric. The company kept its full-year adjusted EBITDA loss forecast between $250 million and $275 million.

Insider-sale activity showed up last week. Director Jeffrey B. Straubel disclosed the sale of 27,106 QuantumScape shares on May 12 in a May 14 Form 4. The shares went for a weighted average of $7.8532 each. Straubel used a Rule 10b5-1 plan to execute the trade, according to the filing.

Rivals are moving fast. Solid Power said in October it’s working with Samsung SDI and BMW on all-solid-state battery tech, while Toyota said Japanese authorities cleared its next-generation and all-solid-state battery development and production plans.

QuantumScape is relying on its partners as well. In the shareholder letter, Jamie Huang-Chu, Corning’s program director of energy materials, said Corning thinks it can help customers build “a better battery at a competitive price.” QuantumScape said it is working with Murata Manufacturing and Corning to scale up ceramic separator production through its Cobra process.

But the risk is still clear. If Eagle Line output stumbles, if field tests fall short, or if interest from auto, defense, or AI data center customers does not become sales, shares could give up last week’s move. QuantumScape points to risks like scaling delays, technical problems, trouble commercializing, issues with partners and the chance it might have to raise more money, which could dilute holders.

Market confidence faces a test in the week ahead. With trading shut until Monday, QS holders have only Friday’s $8.01 close, a Q2 ramp-up pledge and one question: can Eagle Line show enough to support the rebound?

Stock Market Today

  • Aston Martin Shares Plunge 97% Since 2018 IPO, £17,007 Investment Now Worth £442
    May 17, 2026, 5:00 PM EDT. Aston Martin's (LSE: AML) share price has crashed 97.4% since its October 2018 IPO, where it floated at £19 per share valuing the firm at £4.33 billion. Today, shares trade near 49.32p, reducing a £17,007 initial investment to just £442. The luxury carmaker battled management upheavals, including CEO Andy Palmer's 2020 exit, and was heavily impacted by weak demand, US tariffs, and high net debt of £1.5 billion versus a market cap of around £500 million. Despite a Q1 revenue rise of 16% to £270 million and narrowing operating losses, Aston Martin continues to burn cash amid shrinking vehicle development and workforce cuts. Investor sentiment remains cautious amid ongoing financial pressures and volatile market conditions.

Latest articles

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Stock Is Gone From Nasdaq — The $41 Deal Leaves One Last Bet

17 May 2026
Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
Vale Shares Stand Out as Brazil Market Slips, Iron Ore Prices Stay Firm

Vale Shares Stand Out as Brazil Market Slips, Iron Ore Prices Stay Firm

17 May 2026
Vale shares closed at R$83.50 in São Paulo on Friday, up 0.76%, while the Ibovespa fell 0.61%. Vale told U.S. regulators it expects about $1.5 billion more 2026 free cash flow from its iron ore unit, citing market conditions after the Middle East conflict. Iron ore traded near a 52-week high at $110.77 a tonne on May 15. Vale’s Q1 net profit rose 36% to $1.89 billion, missing analyst forecasts.
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over
Previous Story

Apellis Stock Is Gone From Nasdaq — The $41 Deal Leaves One Last Bet

Go toTop